Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CRBU Stock Summary
Top 10 Correlated ETFs
CRBU
In the News
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
Caribou Biosciences, Inc. (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Caribou Biosciences Stock Is Crashing Today
Caribou Biosciences announced that it has paused the development of experimental cell therapy CB-020. The company still has three programs in clinical testing.
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's participation in the following investor conferences:
3 Biotech Stocks You Can Buy and Hold for the Next Decade
Catalyst buys appealing medicines or pharmaceutical assets and gets them out the door. Recursion uses AI and vast biomedical data to discover and exploit leads for new drugs.
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Drug Administration (FDA) just approved the world's first medicine employing CRISPR technology.
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.
Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing
In July, Caribou Biosciences reported positive data from the Antler study of its CAR-T therapy, CB-010, and a $25M investment from PFE. Data from the dose expansion portion of the Antler study are expected in H1'24, but given previous conservative guidance for timelines from CRBU, might come in Q1'24. The Company has $396.7M in cash, which it expects to fund operations into Q4'25.
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate is an off-the-shelf cellular cancer therapy for lymphoma patients.
1 Gene Editing Stock to Buy Now, and 1 to Sell
Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs.
CRBU Financial details
CRBU Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.21 | 0.45 | 0.3 | 0.23 | 0.47 | |
Net income per share | -0.85 | -1.24 | -2.11 | -1.64 | -1.38 | |
Operating cash flow per share | -1.16 | -1.2 | -1.03 | -1.5 | -1.26 | |
Free cash flow per share | -1.19 | -1.25 | -1.13 | -1.61 | -1.42 | |
Cash per share | 1.79 | 0.58 | 11.87 | 4.07 | 4.46 | |
Book value per share | 0.27 | -0.85 | 12.25 | 4.95 | 4.99 | |
Tangible book value per share | 0.27 | -0.85 | 12.25 | 4.95 | 4.99 | |
Share holders equity per share | 0.27 | -0.85 | 12.25 | 4.95 | 4.99 | |
Interest debt per share | 1.55 | 0.06 | 0.46 | 0.32 | 0.37 | |
Market cap | 451.37M | 451.37M | 477.8M | 381.83M | 422.92M | |
Enterprise value | 410.83M | 436.99M | 237.64M | 351.24M | 399.24M | |
P/E ratio | -19.26 | -13.16 | -7.14 | -3.84 | -4.14 | |
Price to sales ratio | 77.98 | 36.52 | 49.78 | 27.57 | 12.27 | |
POCF ratio | -14.1 | -13.59 | -14.69 | -4.2 | -4.53 | |
PFCF ratio | -13.72 | -13.07 | -13.41 | -3.9 | -4.03 | |
P/B Ratio | 60.48 | -19.26 | 1.23 | 1.27 | 1.15 | |
PTB ratio | 60.48 | -19.26 | 1.23 | 1.27 | 1.15 | |
EV to sales | 70.98 | 35.35 | 24.76 | 25.36 | 11.58 | |
Enterprise value over EBITDA | -12.64 | -12.68 | -3.49 | -3.31 | -3.55 | |
EV to operating cash flow | -12.84 | -13.16 | -7.31 | -3.86 | -4.28 | |
EV to free cash flow | -12.49 | -12.66 | -6.67 | -3.58 | -3.81 | |
Earnings yield | -0.05 | -0.08 | -0.14 | -0.26 | -0.24 | |
Free cash flow yield | -0.07 | -0.08 | -0.07 | -0.26 | -0.25 | |
Debt to equity | 5.73 | -0.07 | 0.04 | 0.09 | 0.07 | |
Debt to assets | 0.69 | 0.04 | 0.03 | 0.07 | 0.06 | |
Net debt to EBITDA | 1.25 | 0.42 | 3.52 | 0.29 | 0.21 | |
Current ratio | 5.66 | 1.96 | 15.15 | 9.25 | 11.97 | |
Interest coverage | -8.58K | -1.81K | -8.37K | 12.46 | 0 | |
Income quality | 1.37 | 0.97 | 0.49 | 0.91 | 0.91 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.84 | 1.14 | 2.53 | 2.74 | 1.12 | |
Research and developement to revenue | 4.08 | 2.78 | 5.44 | 5.94 | 3.25 | |
Intangibles to total assets | 0 | -0.07 | -0.01 | -0.03 | 0 | |
Capex to operating cash flow | 0.03 | 0.04 | 0.1 | 0.08 | 0.12 | |
Capex to revenue | -0.15 | -0.11 | -0.33 | -0.51 | -0.34 | |
Capex to depreciation | -1.18 | -1.46 | -3.17 | -4.35 | -3.29 | |
Stock based compensation to revenue | 0.21 | 0.08 | 0.36 | 0.85 | 0.4 | |
Graham number | 2.27 | 4.86 | 24.13 | 13.49 | 12.46 | |
ROIC | -0.52 | 1.57 | -0.17 | -0.3 | -0.28 | |
Return on tangible assets | -0.38 | -0.89 | -0.15 | -0.26 | -0.23 | |
Graham Net | -0.02 | -1.39 | 9.85 | 2.42 | 3.51 | |
Working capital | 46.93M | 11.92M | 365.36M | 232.12M | 310.54M | |
Tangible asset value | 7.46M | -20.95M | 390.67M | 311.37M | 368.4M | |
Net current asset value | 2.54M | -35.18M | 336.66M | 187.35M | 266.27M | |
Invested capital | 5.73 | -0.07 | 0.04 | 0.09 | 0.07 | |
Average receivables | 0 | 4.57M | 6.64M | 6.39M | 4.26M | |
Average payables | 0 | 2.57M | 3.3M | 2.57M | 2.13M | |
Average inventory | 0 | 2.81M | -14.34M | -46.84M | -31.29M | |
Days sales outstanding | 251.11 | 152.37 | 308.95 | 122.91 | 40.85 | |
Days payables outstanding | 39.18 | 27.58 | 1.48K | 114.88 | 323.06 | |
Days of inventory on hand | 49.14 | 25.8 | -11.54K | -6.27K | 0 | |
Receivables turnover | 1.45 | 2.4 | 1.18 | 2.97 | 8.93 | |
Payables turnover | 9.32 | 13.24 | 0.25 | 3.18 | 1.13 | |
Inventory turnover | 7.43 | 14.15 | -0.03 | -0.06 | 0 | |
ROE | -3.14 | 1.46 | -0.17 | -0.33 | -0.28 | |
Capex per share | -0.03 | -0.05 | -0.1 | -0.12 | -0.16 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.06 | 0.06 | 0.06 | 0.28 | 0.04 | |
Net income per share | -0.44 | -0.41 | -0.48 | -0.12 | -0.39 | |
Operating cash flow per share | -0.41 | -0.46 | -0.25 | -0.34 | -0.24 | |
Free cash flow per share | -0.44 | -0.49 | -0.29 | -0.4 | -0.27 | |
Cash per share | 4.06 | 3.74 | 4.22 | 4.04 | 3.72 | |
Book value per share | 4.93 | 4.55 | 4.39 | 4.75 | 4.17 | |
Tangible book value per share | 4.93 | 4.55 | 4.39 | 4.75 | 4.17 | |
Share holders equity per share | 4.93 | 4.55 | 4.39 | 4.75 | 4.17 | |
Interest debt per share | 0.39 | 0.4 | 0.44 | 0.33 | 0.31 | |
Market cap | 383.09M | 324.9M | 261.03M | 400.49M | 506.72M | |
Enterprise value | 352.5M | 299.58M | 222.07M | 323.88M | 483.04M | |
P/E ratio | -3.55 | -3.25 | -2.21 | -10.01 | -3.67 | |
Price to sales ratio | 103.76 | 92.78 | 69.51 | 16.93 | 142.42 | |
POCF ratio | -15.3 | -11.63 | -17.19 | -13.91 | -23.7 | |
PFCF ratio | -14.14 | -10.84 | -14.72 | -11.94 | -21.42 | |
P/B Ratio | 1.27 | 1.17 | 0.97 | 1.01 | 1.38 | |
PTB ratio | 1.27 | 1.17 | 0.97 | 1.01 | 1.38 | |
EV to sales | 95.48 | 85.55 | 59.14 | 13.69 | 135.76 | |
Enterprise value over EBITDA | -11.55 | -9.82 | -6.75 | -22.13 | -13.62 | |
EV to operating cash flow | -14.08 | -10.72 | -14.62 | -11.25 | -22.59 | |
EV to free cash flow | -13.01 | -10 | -12.52 | -9.66 | -20.42 | |
Earnings yield | -0.07 | -0.08 | -0.11 | -0.02 | -0.07 | |
Free cash flow yield | -0.07 | -0.09 | -0.07 | -0.08 | -0.05 | |
Debt to equity | 0.09 | 0.1 | 0.1 | 0.07 | 0.07 | |
Debt to assets | 0.07 | 0.08 | 0.08 | 0.06 | 0.06 | |
Net debt to EBITDA | 1 | 0.83 | 1.18 | 5.23 | 0.67 | |
Current ratio | 9.25 | 8.84 | 7.81 | 14.27 | 11.97 | |
Interest coverage | 7.45 | 10.13 | 0 | 0 | 0 | |
Income quality | 0.93 | 1 | 0.51 | 2.88 | 0.62 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.31 | 2.54 | 2.7 | 0.41 | 2.73 | |
Research and developement to revenue | 6.97 | 7.34 | 7.06 | 1.21 | 8.79 | |
Intangibles to total assets | -0.03 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.08 | 0.07 | 0.17 | 0.17 | 0.11 | |
Capex to revenue | -0.56 | -0.58 | -0.68 | -0.2 | -0.64 | |
Capex to depreciation | -4.07 | -3.45 | -4.14 | -3.01 | -1.15 | |
Stock based compensation to revenue | 0.84 | 0.89 | 0.95 | 0.15 | 1 | |
Graham number | 7.01 | 6.46 | 6.89 | 3.57 | 6.05 | |
ROIC | -0.09 | -0.08 | -0.1 | -0.03 | -0.09 | |
Return on tangible assets | -0.07 | -0.07 | -0.08 | -0.02 | -0.08 | |
Graham Net | 2.41 | 2.7 | 2.72 | 3.41 | 2.93 | |
Working capital | 232.12M | 212.39M | 234.16M | 326.12M | 310.54M | |
Tangible asset value | 311.37M | 278.27M | 269.46M | 398.27M | 368.4M | |
Net current asset value | 187.35M | 170.3M | 188.35M | 291.44M | 266.27M | |
Invested capital | 0.09 | 0.1 | 0.1 | 0.07 | 0.07 | |
Average receivables | 4.83M | 4.75M | 4.29M | 4.44M | 4.5M | |
Average payables | 1.19M | 1.9M | 3.54M | 3.41M | 2.75M | |
Average inventory | -27.56M | -28.85M | -12.17M | -11.88M | 2.73M | |
Days sales outstanding | 113.69 | 124.44 | 89.69 | 19.54 | 97.61 | |
Days payables outstanding | 114.22 | 216.11 | 354.33 | 101.58 | 142.25 | |
Days of inventory on hand | -6.24K | 397.5 | -2.33K | 233.25 | 0 | |
Receivables turnover | 0.79 | 0.72 | 1 | 4.61 | 0.92 | |
Payables turnover | 0.79 | 0.42 | 0.25 | 0.89 | 0.63 | |
Inventory turnover | -0.01 | 0.23 | -0.04 | 0.39 | 0 | |
ROE | -0.09 | -0.09 | -0.11 | -0.03 | -0.09 | |
Capex per share | -0.03 | -0.03 | -0.04 | -0.06 | -0.03 |
CRBU Frequently Asked Questions
What is Caribou Biosciences, Inc. stock symbol ?
Caribou Biosciences, Inc. is a US stock , located in Berkeley of Ca and trading under the symbol CRBU
What is Caribou Biosciences, Inc. stock quote today ?
Caribou Biosciences, Inc. stock price is $5.12 today.
Is Caribou Biosciences, Inc. stock public?
Yes, Caribou Biosciences, Inc. is a publicly traded company.